GFAP and hereditary spastic paraplegia: Taken together, current evidence points to a potential role for GFAP as a biomarker of glial activation in selected subtypes, while its overall utility in HSP will require longitudinal studies in larger, genotype-diverse, cohorts that account for age-related changes and other confounding factors.